Form 4: Disc Medicine CEO Executes Options and Sells Shares Under Pre-Arranged Trading Plan

Disc Medicine, Inc. CEO John D. Quisel executed stock options and subsequently sold a portion of the acquired shares on July 9, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• John D. Quisel, Chief Executive Officer and Director of Disc Medicine, Inc. (IRON), engaged in transactions on July 9, 2025.
• Acquired 34,800 shares of Common Stock by exercising stock options at a price of $9.86 per share.
• Sold 31,207 shares of Common Stock at a weighted average price of $55.2312 per share, with individual sales ranging from $55.00 to $55.99.
• Sold an additional 3,593 shares of Common Stock at a weighted average price of $56.1995 per share, with individual sales ranging from $56.00 to $56.33.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
• Following these transactions, beneficial ownership of Common Stock is 161,828 shares.
• Remaining beneficially owned stock options are 115,375.

Sentiment

Score: 7

Explanation: The transactions represent a planned liquidity event for the CEO, executed at a significant profit margin, which is generally positive for the insider. The use of a 10b5-1 plan mitigates negative interpretations of insider selling, suggesting a pre-arranged financial management strategy rather than a reaction to adverse company developments.

Positives

• CEO John D. Quisel realized significant gains by exercising stock options at $9.86 and selling shares at weighted average prices of $55.2312 and $56.1995.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating planned liquidity rather than a reaction to new negative information, which can mitigate concerns about opportunistic insider selling.

Negatives

• Insider selling by the Chief Executive Officer, even under a Rule 10b5-1 plan, reduces direct ownership and could be interpreted by some investors as a lack of confidence, though this is mitigated by the pre-planned nature.

Future Outlook

NA

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

Industry Context

This Form 4 filing details an insider transaction, which is specific to the individual and company, and does not directly relate to broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: May perceive the insider selling as a signal, though the use of a Rule 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new company-specific information. The reduction in direct ownership by the CEO could be viewed with caution by some investors.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction filing.

Key Dates

Recommendation

Keywords

Disc Medicine, IRON, Form 4, insider trading, stock options, CEO, John D. Quisel, Rule 10b5-1, equity sales